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WHAT THIS PAPER ADDS
 This is the ﬁrst report of results from carotid artery stenting in Sweden through Registry data in Swedvasc. The results conﬁrm data
from randomised trials showing that carotid artery stenting is not as safe as carotid endarterectomy from a national perspective.
However, our single-centre experience shows that it is possible to achieve acceptable results in a consecutive selective case series.a r t i c l e i n f o
Article history:
Received 26 September 2011
Accepted 22 January 2012
Available online 18 February 2012
Keywords:
Registries
Carotid surgery
Carotid artery stenting
Carotid stenosisTo access continuing medical education ques
to www.vasculareducation.com and click on ‘CME’
* Corresponding author. D. Lindström, Departmen
olinska University Hospital, 17176 Stockholm, Swe
fax: þ46 851776642.
E-mail address: David.lindstrom@ki.se (D. Lindströ
1078-5884/$ e see front matter  2012 European So
doi:10.1016/j.ejvs.2012.01.024a b s t r a c t
Objectives: The aim was internal vascular centre quality-control measures to compare single-centre
results with the national perspective, as well as analysing the Swedish results from carotid artery
stenting (CAS) and comparing a relatively high-volume single centre with the Swedish Vascular Registry
(Swedvasc) data. The second aimwas to compare CAS and carotid artery endarterectomy (CEA) outcomes
for the same 7-year period.
Design: Retrospective review of a single high-volume centre (Södersjukhuset (SÖS)) (approximately 30
CAS year1 approximately 90 CEA year1) versus Swedvasc National data.
Materials and methods: All consecutive selective patients treated with CAS at SÖS for a stenosis of the
internal carotid artery (n ¼ 208) or CEA (n ¼ 552) between 2004 and 2011 were compared with all
patients in Swedvasc registered for CAS (n ¼ 258) and CEA (n ¼ 6474). Primary outcome was 30-day
frequency of stroke or death. Secondary outcome was stroke/death/acute myocardial infarction (AMI).
Results: The 30-day frequency of any stroke or death after CAS at SÖS compared to the national data was
2.9% and 7.4%, respectively (P ¼ 0.04). The 30-day AMI/stroke/death frequency was 3.4% and 9.5%,
respectively (P ¼ 0.01). After CEA during the same time period, the Swedvasc national data had a 4.4%
frequency of 30-day stroke and death and 5.8% for AMI/stroke/death.
Conclusions: CAS is not as safe as CEA from a national perspective but our results indicate that a single
centre can achieve acceptable results with CAS.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.In Sweden, nearly 1100 carotid artery endarterectomies (CEAs)
are performed annually and the numbers of carotid artery stentingtions on this paper, please go
t of Vascular Surgery, Kar-
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ciety for Vascular Surgery. Publishe(CAS) procedures are between 50 and 100.1 Södersjukhuset (SÖS)
hospital has the largest total volume of carotid interventions in
Sweden and performs around 10% of all CEAs and 45% of all CAS
procedures in Sweden. The safety of CAS as compared to CEA has
been questioned worldwide as well as in Sweden.2 In most studies,
CAS has been associated with a higher risk of stroke or death than
CEA. A potential advantage of CAS is a decreased risk of peri-
procedural myocardial infarction.3,4 There are no ofﬁcial Swedish
guidelines on selection criteria for CAS but, in international reports,
a number of indications have been suggested: post-radiationd by Elsevier Ltd. All rights reserved.
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restenosis after CEA, severe cervical spine arthritis, surgically
inaccessible carotid stenosis, contralateral recurrent laryngeal
nerve injury and contralateral internal carotid artery occlusion.5 A
relative contraindication to CAS is octogenarians where high
complication rates have been reported from several trials.6
Evidence on protection devices used during CAS is scarce. The
ﬂow reversal system, Neuro Protection System (NPS), has some
theoretical advantages over standard ﬁlters, and data on the
frequency of micro-embolisation are promising when compared to
ﬁlters.7 During follow-up after CAS, the relatively high frequency of
restenosis (often 10%, range 5e50) is another important issue.8
The objectives of this study were internal vascular centre
quality-control measures to compare single-centre results with the
national perspective. In practice, to investigate if our (by Swedish
standards) high-volume centre and the Swedish national CAS
results are different and if national CAS results differ from national
CEA results. In addition, wewanted to analyse our rate of restenosis
measured by duplex ultrasound (DUS) at 1 year.
Methods
A retrospective single-centre review of all consecutive patients
treated with CAS between 25 November 2004 and 27 April 2011 at
SÖS, a university hospital in Stockholm, Sweden, was conducted.
No CAS procedures were performed before 25 November 2004.
These data were compared to results from the National Swedish
Registry of Vascular Surgery (Swedvasc) where data from all
patients in Sweden treatedwith CEA or CAS during the same period
were extracted. The study was approved by the regional ethics
committee in Stockholm (No 2011/436-31/4).
Data from SÖS
Procedure data were prospectively recorded; data on compli-
cations were retrospectively recorded from the computerised chart.
Data on deaths were collected from the Registry of the Total Pop-
ulation in Sweden. Stroke was deﬁned as sudden onset of focal
neurological deﬁcit that persists for more than 24 h. Patients with
symptoms within the last 180 days were considered symptomatic,
thereafter asymptomatic.
Planning and technique of CAS procedure at SÖS
The pre-procedural workup routine consisted of DUS. In addi-
tion, the majority of our patients (62%) had a computerised
tomography angiography or a magnetic resonance imaging (13%) to
estimate vessel anatomy and suitability for the procedure. The
remaining 25% had a procedural digital subtraction angiography of
the arch and neck vessels before the decision to treat, all at the
same session. The decision (at SÖS hospital) for type of treatment is
made after discussions between vascular surgeons and interven-
tional radiologists about suitability for the different procedures. If
needed, the anaesthesiologists are also involved. Patients were
considered eligible for CAS based on anatomical or co-morbidity
reasons, making many of them otherwise at presumed high risk
for surgery (Table 2). The formal decision is always taken by
a vascular surgeon. In cases where there are uncertainties about the
indication for invasive treatment at all, neurologists are also
involved. All CAS procedures were performed in an endovascular
suite using monoplane C-arm angiography equipment. The proce-
dures were performed by three experienced interventional radi-
ologists assisted by vascular surgeons. Routinely, the procedures
were carried out under local anaesthesia and conscious sedation.
Intra-arterial blood pressure and electrocardiogram (ECG) werecontinuously monitored by an anaesthesiologist. From 2010
onwards, cerebral oximetry was also monitored by Fore-Sight,
(CAS Medical Systems Inc, Branford, CT, USA). Standard CAS
protocols were used regarding the Seldinger technique access to
the femoral artery and subsequent catheterisation of the common
carotid artery. Pre-dilatation was performed when necessary, fol-
lowed by stenting and post-dilatation. A variety of cerebral
protection devices were used including ﬂow reversal (NPS; W. L.
Gore and Associates, Flagstaff, AZ, USA). No patient was treated
without a protection device. Femoral artery access was used in all
patients. All patients were given heparin, and activated clotting
time (ACT) was monitored with a goal of 250e300.9 All patients
who were tolerant were given dual anti-platelet therapy with
acetylsalicylic acid (ASA) and clopidogrel. Clopidogrel was started
on the day before the procedure with a loading dose of 300 mg.
Duplex criteria of restenosis
According to our protocol, all patients treated with a CAS had
a 1-month and 1-year post-procedure clinical follow-up in addition
to a DUS. The criteria for >50% in-stent stenosis (according to
european carotid surgery trial (ECST) grading) was ﬂow velocity at
the most narrow part of the stented vessel 1.5 m s1 and an
internal carotid arterial/common carotid arterial (ICA/CCA) velocity
quota of 2.2 measured at a ﬂow angle of 50e60.10,11
Swedvasc data
Swedvasc includes all centres performing carotid procedures in
the country. Follow-up includes a 30-day clinical control with
registration of complications. Data on any death are retrieved
directly from the Swedish National Population Registry and are
updated monthly. In May 2008, a new version of the Swedvasc
database was launched (2.0). The new version included an update
with more strict deﬁnitions on risk factors and outcomes compared
to the previous Swedvasc 1.0. Stroke within 30 days in this study
includes all variables for ipsilateral, contralateral and verte-
brobasilar ischaemic stroke and also intracerebral bleeding. Follow-
up in Swedvasc 2.0 is limited to 30 days.
All patients treated with CAS or CEA between November 2004
and April 2011 were included. Since a large part (45%) of the
Swedish CAS procedures was performed at SÖS, these procedures
were excluded from the National Swedvasc result to make
a comparison meaningful. Only procedures for internal carotid
artery stenosis were included in this report, and interventions
solely to the common carotid were excluded. Indications other than
ICA stenoses were also excluded (dissections, aneurysms, etc.). For
endovascular interventions only bare metal stenting was included,
and covered stent grafts or percutaneous transluminal angioplasty
(PTAs) alone were excluded. CAS cases with synchronous intra-
cranial or aortic arch interventions were also excluded.
Statistical analyses
Single-centre CAS outcome was compared to national CAS
outcome. National CAS outcome was compared to national CEA
outcome. Primary end point was periprocedure stroke/death and
stroke/death/AMI. Secondary end point was restenosis after 1 year.
Outcome data were also reported separately for asymptomatic and
symptomatic patients. In addition, the procedures were dicho-
tomised in ‘high-risk’ or ‘average-risk’ CAS according to number of
baseline risk factors. ‘High-risk’ CAS was deﬁned as two or more
risk factors out of age >70 years, heart disease, pulmonary disease
and renal dysfunction. Continuous data are presented with mean
and standard deviation (SD). Two-sided Fisher’s test was used for
Table 2
Indications for CAS at SÖS.
% (n)
Randomized within ICSS/ACST2 25 (51)
Restenosis after previous CEA/CAS 11 (22)
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test was used for non-normal distributed data. Statistical signiﬁ-
cance was set at P < 0.05. Data were analysed using Statistical
Package for the Social Sciences (SPSS) version 18.0.0 (SPSS, Chicago,
IL, USA).Severe co-morbidity 27 (56)
Post-radiation therapy 6 (12)
Surgically inaccessible stenosis 7 (15)
Contralateral laryngeal nerve injury 0.5 (1)
Patients’ preference 8 (17)
Previous neck surgery 1 (2)
No speciﬁed reason 15 (32)
Total 100.0 (208)Results
In all, there were 221 consecutive carotid stents placed at SÖS;
this analysis is restricted to those treated due to stenosis of the
internal carotid artery (n ¼ 208). During the same time period, 552
standard CEA procedures were performed at SÖS, resulting in
a relative CAS frequency of 38%. Of all CAS procedures done in
Sweden during the study period, 45% were done at SÖS. Of all CEAs
done in Sweden, approximately 10% were performed at SÖS during
the study period.Patients’ characteristics CAS
In Table 1, the SÖS (n ¼ 208) and Swedvasc (n ¼ 258) national
baseline data for patients treated with CAS are presented. Mean age
was 71 (SD 8.5) and 69 (SD 8.3), respectively. The indication was
a symptomatic stenosis in 53% at SÖS and 58% in Swedvasc. The
median time between index symptom and carotid intervention in
Swedvasc was not available in Swedvasc 1.0 and could therefore not
be calculated for the whole study period. The median time for CAS
in Swedvasc 2.0 (the later period; May 2008 until June 2011) was 13
(interquartile range (IQR) 6e25) days and for CEA 11 (IQR 6e22);
the corresponding median time for CAS and CEA at SÖS was 8
days (IQR 5e28) and 7 days (IQR 4e16), respectively. The medianTable 1
Baseline characteristics for CAS patients treated at SÖS and national Swedvasc data.
Södersjukhuset
(n ¼ 208)
Swedvasc
(n ¼ 258)a
Pc
Male Sex 68% (141) 74% (192) NS
Age mean (SD) 71 (8.5) 69 (8.3) 0.01
Symptomatic 53% (111) 58% (149) NS
TIA 47% (52) 35% (52)
Ischaemic stroke 38% (42) 43% (64)
Amaurosis fugax 15% (17) 22% (33)
Asymptomatic 47% (97) 42% (109)
Days from index symptom
until CAS, symptomatic,
2008e2011
8 (IQR 5e28) 13 (IQR 6e25) NS
Smokingd
Missing data
37% (66)
14%
43% (81)
26%
NS
Diabetic
Missing data
29% (61)
e
29% (61)
19%
NS
Pulmonary disease
Missing data
11% (22)
e
18% (28)
39%
NS
Renal dysfunction (crea > 150)
Missing data
4% (8)
e
5% (11)
18%
NS
Heart diseaseb
Missing data
46% (94)
2%
61% (108)
31%
<0.01
Treated hypertension 81% (169)
e
81% (173)
17%
NS
High risk CASe
Average risk CAS
Missing data
35% (72)
65% (132)
2%
41% (56)
59% (80)
47%
NS
NS ¼ Non signiﬁcant.
a SÖS excluded from National data.
b Includes; coronary artery disease, heart failure, atrial ﬁbrillation, previous heart
surgery.
c Fisher’s test for categorical data and t-test for continuous data, ManneWhitney
test for waiting time variable.
d Includes current smoking and those who have quit within the last ﬁve years.
e High risk deﬁned as two or more risk factors out of; age > 70 years, heart
disease, pulmonary disease, renal dysfunction.number of days from index symptom until CAS at SÖS for thewhole
study period (2004e2011) was 14 days (IQR 7e41).
A protection device was used in all CAS cases performed at SÖS;
ﬂow reversal in 57% (n ¼ 118) and distal ﬁlters of various types in
43% (n ¼ 90). The indications for CAS are shown in Table 2; these
data were not available for the national cohort.
Thirty-day results from SÖS
Frequency of all stroke or deaths within 30 days was 2.9% (6/
208), and AMI/stroke/death was 3.4% (7/208) as shown in Table 3.
Results were generally better for those younger than 70 years (2.4%
AMI/stroke/death) compared to those 70 years (4.0% AMI/stroke/
death), although the difference was not statistically signiﬁcant
(P ¼ 0.7). This difference was even more pronounced looking at
those <80 years as compared to those 80 years (2.9 vs. 5.7%,
P¼ 0.34). Any stroke or death occurred among 3/118 patients (2.5%)
when reversed ﬂow was used and among 3/90 (3.3%) when ﬁlter
was used (P ¼ 1.0). When comparing symptomatic versus asymp-
tomatic, the stroke or death frequency was 2.7% (3/111) and 3.1% (3/
97), respectively (P ¼ 1.0).
Results from CEA at SÖS during the same time period were
withdrawn from Swedvasc. Any stroke or death occurred among
4.0% (22/549). CEA results are summarised in Table 4.
Thirty-day results from Swedvasc, CAS and CEA
For the whole period, there were 6474 CEAs and 258 CASs
registered nationally; the CAS procedures were performed at nine
other centres. National CEA data include SÖS. In average, the other
centres performed 29 CAS procedures each, range 1e119. After CEA,
the 30-day frequency of stroke or death was 4.4% (277/6324; 2.3%
missing data). After CAS, the 30-day frequency of stroke or death
was 7.4% (18/243; 5.8% missing data). AMI/stroke/death occurredTable 3
30-day outcome in patients treated with CAS at SÖS compared to Swedish national
CAS data.
SÖS CAS n ¼ 208 Swedvasc e CASa
n ¼ 258b
Pc
Any stroke % (n) 1.9 (4) 5.4 (13/242) NS
Death % (n) 1.0 (2) 2.3 (6) NS
AMI % (n) 1.4 (3) 2.9 (7/242) NS
Stroke or death % (n) 2.9 (6) 7.4 (18/243) 0.04
Among symptomatic % (n) 2.7 (3/111) 4.9 (7/142) NS
Among asymptomatic % (n) 3.1 (3/97) 10.9 (11/101) 0.0495
Among high risk % 5.6% (4/72) 16.7% (9/54) NS
Among average risk % 1.5% (2/132) 3.9% (3/76) NS
Stroke or death or AMI % (n) 3.4 (7) 9.5 (23/243) 0.01
NS ¼ Non signiﬁcant.
a SÖS excluded from national data.
b Missing data makes n differ from 258 in rows below.
c Fisher’s test.
Table 4
30-day outcome in patients treated with CEA at SÖS compared to Swedish national
CEA data.
SÖS CEA n ¼ 552a Swedvasc CEA
n ¼ 6474a
Pb
Any stroke % (n) 3.8 (21/549) 4.0 (250/6322) NS
Death % (n) 0.5 (3/552) 0.8 (53/6472) NS
AMI % (n) 2.7 (15/548) 1.8 (113/6314) NS
Stroke or death % (n) 4.0 (22/549) 4.4 (277/6322) NS
Among symptomatic % (n) 3.7 (16/428) 4.4 (220/5007) NS
Among asymptomatic % (n) 5.0 (6/121) 4.0 (53/1315) NS
Stroke or death or AMI % (n) 6.2 (34/548) 5.8 (368/6321) NS
NS ¼ Non signiﬁcant.
a Missing data makes n differ in rows below.
b Fisher’s test.
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symptomatic versus asymptomatic, the stroke or death frequency
after CEA was 4.4% (220/5007) and 4.0% (53/1315), respectively
(P ¼ 0.59). Corresponding ﬁgures after CAS were 4.9% (7/142) for
the symptomatic group and 10.9% (11/101) for the asymptomatic
group (P ¼ 0.09).
Thirty-day national CAS results from Swedvasc including SÖS data
To deliver a complete national ﬁgure for Swedish CAS results,
the outcomes were also calculated using both Swedvasc and SÖS
data. The overall stroke and death rate was 5.3% (24/451), and
corresponding numbers were 4.0% (10/253) and 7.1% (14/198) for
symptomatic and asymptomatic patients, respectively. The late
results from Swedvasc 2.0 (2008e2011) were better than the early
Swedvasc 1.0 results (2004e2008) e 3.6% stroke or death versus
6.4%, respectively, although not statistically signiﬁcant (P ¼ 0.20).
There were also fewer centres performing CAS during the later
study period (seven vs. nine).
One-year results from SÖS
By 24 June 2011, there were 183 CAS procedures with a post-
operative time span of more than 1 year. Of these, nine out of 183
were dead (4.9%) and the rate for ipsilateral stroke or death within
1 year was 13 out of 183 (7.1%). Data on ipsilateral stroke were
missing on 3/183 (1.6%). Causes of death were: myocardial infarc-
tion, two; unknown, two; cerebral bleeding, one; amyotrophic
lateral sclerosis, one; perforated duodenal ulcer one; pulmonary
ﬁbrosis one; and trauma one.
Freedom from restenosis and target lesion revascularisation e SÖS
One-year DUS was performed in 90% (157/174). Median time to
the DUS was 375 days (IQR 362e426). There were 141 patients
(90%) who were free of restenosis at 1-year follow-up; one patient
had an asymptomatic occlusion (0.6%). Out of the 16 patients who
were diagnosed with a restenosis, six patients (3.8%) underwent
target lesion revascularisation (TLR); two of these patients were
symptomatic.
Discussion
Our report shows that it is possible to achieve acceptable results
with CAS at a single centre, and also that CAS from a national
perspective is not as safe as CEA. Especially among the asymp-
tomatic group, the national outcome is alarming with 10.9% stroke
and death among 101 patients. For those patients not suitable for
standard open repair, a CAS procedure could be an alternative inselected cases. Our study did not have sufﬁcient power to analyse
the ﬂow reversal system; this system has had low stroke rates on
preliminary reports,12,13 although larger clinical data are missing.
This system has better potential to reduce micro-emboli compared
to standard ﬁlters, and the primary difference between these two
methods seemed to be related to lower frequency of embolisation
during the protection phase with ﬂow reversal system. When
establishing access, the ﬂow reversal system still causes much more
micro-emboli than conventional open surgery does before cross-
clamping.7
Our single-centre series includes all patients treated at our
centre and therefore includes a learning curve. The national data
also include a learning curve for many centres involved e very few
centres in Sweden performed CAS before November 2004. Looking
at randomised trials comparing CAS with CEA for symptomatic
patients, the international carotid stenting study (ICSS) trial
reported an 8.0% frequency of any stroke/death at 120 days after
CAS;14 furthermore, the stent-protected angioplasty versus carotid
endarterectomy (SPACE) trial reported a frequency of 7.7% of any
stroke or death at 30 days after CAS15 and The endarterectomy
versus angioplasty in patients with symptomatic severe carotid
stenosis (EVA 3S) reported a 9.6% frequency.16 Lastly, carotid
revascularization endarterectomy versus stenting trial (CREST),
studying both symptomatic and asymptomatic patients, reported
a 4.4% periprocedural stroke or death frequency in total, among
symptomatic patients 6.0% and for the asymptomatic 2.5%.17 In the
light of these trials, the Swedish national data are not surprising
and have similarities although the national results from CAS on
asymptomatic patients are very poor, 7.1% stroke or death among
198 cases. To some extent there seems to have been an adaption to
these early poor results since nine centres reported CAS
2004e2008, seven centres after 2008 and only six after 2010. The
total stroke and death frequency after all CASs have also been
reduced from 6.4% to 3.6%.
Previous meta-analyses have shown that the superiority of CEA
over CAS disappears in patients aged <70 years.3,4,18 We also found
the results for CAS to be better in younger patients, although not
signiﬁcant in this relatively small series. We had similar results for
both asymptomatic and symptomatic patients but larger studies
often ﬁnd symptomatic patients to have worse outcomes. Another
issue when dealing with a population seeking information on the
internet is that in spite of receiving information on the higher risk
with CAS, some asymptomatic patients still prefer this compared to
best medical therapy or surgery.19 We had some similar experi-
ences with patients arguing for the procedure without any strict
indication.
Some limitations with this study are worth mentioning. The
sample size in our single-centre series is small and does not allow
a regression analysis to compare outcome adjusted for co-
morbidities with national data. Furthermore, data from Swedvasc
are not as complete as the single-centre series and have missing
values on baseline characteristics and 30-day outcome; on the
other hand, the missing outcome data from the registry would
probably increase the frequency of complications and therefore our
conclusions would still be valid. When comparing the Swedvasc
and the SÖS CAS groups the SÖS cohort is older and the Swedvasc
cohort has more patients with heart disease. Overall, the co-
morbidities are slightly more present in the Swedvasc cohort but
the frequency of missing data is also much higher in Swedvasc data.
In this material baseline risk factor reporting in Swedvasc was
missing in 0e39% and this is deﬁnitively something the Swedvasc
Registry needs to deal within the future. Furthermore, the high-risk
classiﬁcation revealed no explanation of the outcome differences
between the two groups. Another limitation that may bias all
single-centre studies and surgeon-driven registries is that
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neurologists.
The strength of our single-centre cohort is that it is a consecu-
tive selective series. We have no missing cases for the 30-day
follow-up, and the combination with the death registry makes
the validity for the stroke and death variable very reliable. In
addition, data on deaths were derived directly from the national
registry for both Swedvasc data and SÖS data and therefore not
biased and with extremely few missing cases. The validity of
Swedvasc has also previously been reported to be very high, and
external validity for carotid surgery was 93.4%.20
In conclusion, CAS is not as safe as CEA from a national
perspective. Nevertheless, our single-centre experience shows that
it is possible to achieve acceptable results in a consecutive selective
case series. The CAS procedure should be limited to those cases that
are not suitable for open surgery.
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